Skip to main content
AMGN
NASDAQ Life Sciences

Roche's Obesity Drug Shows Strong Diabetes Data, Threatening Amgen and Lilly

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$392.43
Mkt Cap
$212.555B
52W Low
$269.77
52W High
$447.03
52W Position info
45% above low
Off High info
12% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

AMGN sits 45% above its 52-week low of $269.77.

Summary

Roche's enicepatide delivered 15.5% weight loss and significant HbA1c reduction in a mid-stage trial for obese/overweight patients with type 2 diabetes, with 62% reaching non-diabetic HbA1c levels. This is a direct competitive threat to Amgen's obesity pipeline and Eli Lilly's market leadership. The data strengthens Roche's position in the $100B+ obesity market and raises the bar for Amgen's own candidates. Amgen shares already fell 9% earlier this month on Novartis's cardiovascular failure, and this adds pressure on its obesity program. Watch for Amgen's own obesity data readouts and Roche's planned late-stage trials in H1 2027.

At the time of this announcement, AMGN was trading at $392.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212.6B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $447.59 info
Change: -$29.81 (-6%) info
Market Cap: $242.469B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $447.59 info
Change: -$17.33 (-4%) info
Market Cap: $242.469B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $447.59 info
Change: -$15.41 (-3%) info
Market Cap: $242.469B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $447.59 info
Change: -$12.98 (-3%) info
Market Cap: $242.469B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $447.59 info
Change: -$1.20 (-0.27%) info
Market Cap: $242.469B info